Hormone refractory breast cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hormone refractory breast cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy https://clinicaltrials.eu/trial/a-study-of-datopotamab-deruxtecan-for-patients-with-hormone-receptor-positive-her2-negative-advanced-or-metastatic-breast-cancer-that-did-not-respond-to-hormone-therapy/ Wed, 29 Apr 2026 15:07:46 +0000 https://clinicaltrials.eu/trial/a-study-of-datopotamab-deruxtecan-for-patients-with-hormone-receptor-positive-her2-negative-advanced-or-metastatic-breast-cancer-that-did-not-respond-to-hormone-therapy/ This study is looking at a type of cancer called breast cancer that has spread to other parts of the body or cannot be removed by surgery. The cancer being studied is a specific type that is hormone receptor-positive and HER2 IHC 0, which means the cancer cells have receptors for hormones but do not have a protein called HER2 on their surface, or have very low levels of it. The cancer must also be resistant to or not suitable for hormone-based treatments, which are medications that work by blocking hormones that help cancer grow. The treatment being tested in this study is called Datopotamab deruxtecan, which is given through a vein as an infusion. This medication is a type of drug that combines an antibody with a cancer-fighting substance to target cancer cells more directly.

The purpose of this study is to see how well Datopotamab deruxtecan works in stopping the cancer from getting worse, which is measured by looking at how long patients live without their cancer progressing. The study will also look at how safe the medication is by checking for side effects such as mouth sores, eye problems, and other serious reactions. Patients in this study will receive the study medication and will be monitored regularly to see how their cancer responds to treatment and to check for any side effects. The study will also measure how many patients have their cancer shrink or stay the same size, how long any positive response to treatment lasts, and how long patients survive after starting the treatment.

During the study, doctors will take images and samples to track how the cancer is responding to the medication. The study is designed for patients whose cancer has a specific pattern of hormone receptors and HER2 levels, and who are not suitable candidates for another similar medication. Patients will need to have a certain level of general health and organ function to participate, and their cancer must be measurable or visible on scans. The study will continue for several years to collect information about how well the treatment works over time.

]]> Study on Oxybutynin and Venlafaxine for Reducing Hot Flashes in Women Undergoing Endocrine Therapy After Breast Cancer https://clinicaltrials.eu/trial/study-on-oxybutynin-and-venlafaxine-for-reducing-hot-flashes-in-women-undergoing-endocrine-therapy-after-breast-cancer/ Wed, 29 Apr 2026 14:30:19 +0000 https://clinicaltrials.eu/trial/study-on-oxybutynin-and-venlafaxine-for-reducing-hot-flashes-in-women-undergoing-endocrine-therapy-after-breast-cancer/ The RED FLASH study is focused on helping women who have had breast cancer and are experiencing hot flashes as a side effect of their ongoing treatment. Hot flashes are sudden feelings of warmth, often intense, that can occur in women undergoing endocrine therapy after breast cancer. This study is comparing two treatments: oxybutynin and venlafaxine. Oxybutynin is usually used to treat bladder issues, while venlafaxine is commonly used as an antidepressant. Both medications are being tested to see how well they can reduce the number and severity of hot flashes.

The purpose of the study is to find out which of these two medications is more effective in reducing hot flashes. Participants will receive both treatments at different times during the study, allowing researchers to compare the effects within the same individual. This approach is known as a “cross-over” study. The study will last for several weeks, during which participants will take one medication for a period, then switch to the other. Throughout the study, participants will keep a daily record of their hot flashes in a Hot Flash Diary.

In addition to tracking hot flashes, the study will also look at other factors such as any side effects, sleep quality, overall quality of life, and mental health aspects like anxiety and depression. The study aims to provide valuable information that could help improve the quality of life for women dealing with hot flashes after breast cancer treatment.

]]>